See more : Unictron Technologies Corporation (6792.TW) Income Statement Analysis – Financial Results
Complete financial analysis of Antisense Therapeutics Limited (ATHJF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Antisense Therapeutics Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Surgutneftegas Public Joint Stock Company (SGTPY) Income Statement Analysis – Financial Results
- NAMI Corp. (NINK) Income Statement Analysis – Financial Results
- Office Properties Income Trust (OPINL) Income Statement Analysis – Financial Results
- Cofidur S.A. (ALCOF.PA) Income Statement Analysis – Financial Results
- Edenville Energy Plc (EDL.L) Income Statement Analysis – Financial Results
Antisense Therapeutics Limited (ATHJF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.antisense.com.au
About Antisense Therapeutics Limited
Antisense Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase II clinical trial for the treatment of multiple sclerosis, Duchenne Muscular Dystrophy, asthma, and other inflammatory indications. The company's product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. Antisense Therapeutics Limited was incorporated in 2000 and is based in Toorak, Australia.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.97M | 1.58M | 1.78M | 577.76K | 668.43K | 586.79K | 272.42K | 69.12K | 1.00M | 3.86M | 1.22M | 1.30M | 6.40M | 762.37K |
| Cost of Revenue | 62.15K | 95.20K | 89.22K | 103.32K | 107.60K | 5.38K | 6.41K | 207.81K | 317.38K | 205.35K | 153.48K | 223.63K | 0.00 | 0.00 |
| Gross Profit | 2.91M | 1.48M | 1.69M | 474.45K | 560.83K | 581.41K | 266.01K | -138.70K | 682.62K | 3.66M | 1.07M | 1.07M | 6.40M | 762.37K |
| Gross Profit Ratio | 97.91% | 93.97% | 94.98% | 82.12% | 83.90% | 99.08% | 97.65% | -200.68% | 68.26% | 94.69% | 87.46% | 82.73% | 100.00% | 100.00% |
| Research & Development | 10.70M | 10.16M | 4.54M | 4.91M | 1.90M | 1.76M | 975.40K | 1.10M | 1.85M | 1.68M | 2.15M | 1.55M | 5.13M | 3.37M |
| General & Administrative | 551.60K | 3.05M | 2.92M | 3.56M | 4.46M | 1.19M | 939.44K | 1.97M | 1.91M | 2.00M | 1.02M | 1.11M | 2.29M | 1.58M |
| Selling & Marketing | 1.38M | 1.32M | 1.14M | 836.34K | 628.48K | 372.77K | 343.10K | 765.77K | 775.03K | 928.32K | 815.47K | 765.12K | 91.84K | 0.00 |
| SG&A | 4.04M | 3.05M | 2.92M | 3.56M | 4.46M | 1.82M | 1.64M | 1.97M | 1.91M | 2.00M | 1.95M | 1.98M | 2.29M | 1.58M |
| Other Expenses | 0.00 | 1.59M | 1.78M | 629.20K | 740.10K | 0.00 | 0.00 | 391.75K | 425.86K | 679.49K | 0.00 | 0.00 | 167.34K | 278.94K |
| Operating Expenses | 14.74M | 13.34M | 7.61M | 8.68M | 6.67M | 3.58M | 2.61M | 3.29M | 4.07M | 3.89M | 4.08M | 3.53M | 7.52M | 5.60M |
| Cost & Expenses | 14.80M | 13.34M | 7.61M | 8.68M | 6.67M | 3.58M | 2.62M | 3.29M | 4.07M | 3.89M | 4.24M | 3.75M | 7.52M | 5.60M |
| Interest Income | 615.48K | 384.92K | 34.18K | 4.18K | 30.53K | 66.17K | 25.55K | 71.05K | 132.10K | 52.35K | 0.00 | 0.00 | 416.49K | 486.83K |
| Interest Expense | 3.60K | 8.15K | 11.91K | 10.73K | 12.54K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 11.58K | 95.20K | 89.22K | 103.32K | 107.60K | 5.38K | 6.41K | 4.89K | 5.88K | 8.17K | 9.75K | 8.04K | 8.64K | 460.93K |
| EBITDA | -11.90M | -11.37M | -5.83M | -8.10M | -5.99M | -3.58M | -2.61M | -3.21M | -3.07M | -16.75K | -3.02M | -2.46M | -1.11M | -5.14M |
| EBITDA Ratio | -400.93% | -838.67% | -423.08% | -1,485.03% | -981.20% | -609.72% | -959.43% | -4,648.36% | -306.65% | -0.43% | -246.93% | -189.82% | -17.38% | -573.87% |
| Operating Income | -11.83M | -13.34M | -7.61M | -8.68M | -6.67M | -3.58M | -2.62M | -3.22M | -3.07M | -24.92K | -3.03M | -2.47M | -1.12M | -4.84M |
| Operating Income Ratio | -398.65% | -844.70% | -428.10% | -1,502.91% | -997.30% | -610.64% | -961.79% | -4,655.44% | -307.24% | -0.65% | -247.73% | -190.44% | -17.52% | -634.33% |
| Total Other Income/Expenses | -86.71K | -94.82K | -67.70K | -58.44K | -17.94K | -530.22K | -262.13K | 462.81K | 557.96K | 731.84K | 18.71K | 11.64K | 583.83K | 0.00 |
| Income Before Tax | -11.92M | -11.38M | -5.81M | -8.06M | -5.91M | -3.52M | -2.60M | -2.75M | -2.51M | 706.92K | -3.01M | -2.45M | -537.14K | -4.84M |
| Income Before Tax Ratio | -401.57% | -720.31% | -326.89% | -1,395.14% | -883.89% | -600.08% | -955.66% | -3,985.82% | -251.44% | 18.30% | -246.20% | -189.54% | -8.39% | -634.33% |
| Income Tax Expense | -2.35M | -376.77K | -22.27K | 6.55K | -17.99K | -576.69K | -272.42K | -71.05K | -132.10K | -52.35K | 0.00 | 0.00 | 1.60M | 278.94K |
| Net Income | -11.92M | -11.38M | -5.81M | -8.06M | -5.91M | -2.94M | -2.33M | -2.75M | -2.51M | 706.92K | -3.01M | -2.45M | -2.14M | -4.84M |
| Net Income Ratio | -401.57% | -720.31% | -326.89% | -1,395.14% | -883.89% | -501.80% | -855.66% | -3,985.82% | -251.44% | 18.30% | -246.20% | -189.54% | -33.39% | -634.33% |
| EPS | -0.01 | -0.02 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 | -0.01 | 0.00 | -0.02 | -0.02 | -0.03 | -0.06 |
| EPS Diluted | -0.01 | -0.02 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 | -0.01 | 0.00 | -0.02 | -0.02 | -0.03 | -0.06 |
| Weighted Avg Shares Out | 881.21M | 668.85M | 631.79M | 540.98M | 454.51M | 386.11M | 194.27M | 161.11M | 175.21M | 157.86M | 144.10M | 141.09M | 82.79M | 77.69M |
| Weighted Avg Shares Out (Dil) | 881.15M | 668.85M | 634.29M | 540.98M | 455.83M | 386.10M | 194.63M | 161.53M | 175.20M | 157.93M | 144.09M | 141.19M | 82.79M | 77.69M |
Source: https://incomestatements.info
Category: Stock Reports